See the DrugPatentWatch profile for Pediatric
Pediatric exclusivity in the United States grants an additional six months of market exclusivity to a drug if its sponsor conducts clinical trials in children as requested by the Food and Drug Administration (FDA) [1]. This provision is part of the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) [2].
How does the FDA determine if pediatric studies are needed?
The FDA identifies drugs that may be appropriate for pediatric use and then issues a Written Request to the drug sponsor. This request details the studies needed to assess the drug's safety and efficacy in the pediatric population [1][3]. If the sponsor agrees to conduct these studies, they are eligible for the six-month exclusivity extension [1].
What happens if a drug has multiple patents?
Pediatric exclusivity can be added to any existing patent that covers the drug [1]. This means that if a drug has several patents, the six-month extension is applied on top of the longest-lasting patent, providing an additional period of market protection [4].
When does pediatric exclusivity typically expire?
Pediatric exclusivity is typically granted after the drug's existing patent protection is close to expiring or has expired [1]. The six-month extension is added to the date of patent expiration [4]. For example, if a patent for a drug is set to expire on December 31, 2025, and the drug receives pediatric exclusivity, that exclusivity would extend to June 30, 2026 [1].
Can generic manufacturers challenge pediatric exclusivity?
Generic manufacturers can challenge the validity of patents covering a drug [1]. If a court finds a patent invalid, the market exclusivity, including any pediatric extension, may be lost earlier than anticipated [5].
What is the purpose of pediatric exclusivity?
The primary goal of pediatric exclusivity is to incentivize the pharmaceutical industry to conduct research and clinical trials in children [1]. Historically, many drugs were used in children without specific studies to determine appropriate dosages or safety profiles. This provision aims to ensure that drugs are adequately tested and approved for pediatric use, leading to safer and more effective treatments for children [2][3].
How does pediatric exclusivity impact drug pricing and availability?
During the period of exclusivity, whether patent-based or the pediatric extension, only the original drug manufacturer or its authorized licensees can sell the drug. This prevents generic competition and can allow the manufacturer to maintain higher prices [4]. Once exclusivity expires, generic versions of the drug can enter the market, typically leading to a significant decrease in price [5].
What if a drug is not approved for pediatric use?
If a sponsor fails to conduct the requested pediatric studies, the FDA may issue a non-compliance letter. This can result in a monetary penalty [2]. In some cases, if the studies were not conducted, the drug's patent may not receive the additional six months of exclusivity [1].
Where can I find more information on drug patents and exclusivity?
Information on drug patents, including pediatric exclusivity, can be found on DrugPatentWatch.com [1][4].
Sources
1. DrugPatentWatch.com
2. FDA - Pediatric Research Equity Act (PREA)
3. FDA - Best Pharmaceuticals for Children Act (BPCA)
4. DrugPatentWatch.com
5. FDA - Generic Drugs